Screener
Allogene Therapeutics ALLO Business Segments
| Q2 '26 | ||
|---|---|---|
| Remaining performance obligation, extinguished by Product | ||
| Know-How Developed In Future Periods | $2.7M— | |
| Manufacturing License, Know-How | $1.9M— |
FAQ
- How does Allogene Therapeutics break its business down?
- Allogene Therapeutics (ALLO) reports remaining performance obligation, extinguished by product across 2 parts — Know-How Developed In Future Periods and Manufacturing License, Know-How. Each is extracted from the segment footnotes and tracked over time.
- Where does Allogene Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Allogene Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
